N/A N=5 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus (CLE)
Primary: Cutaneous Lupus Area and Severity Index (CLASI) — 21.4; 10.8; 8.6; 5.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 ACT for Life: a Brief Intervention for Maximizing Recovery After Suicidal Crises
Suicide · Psychiatric Rehabilitation
Primary: Client Satisfaction Questionnaire - 8 — 28 Participants
Phase 4 N=33 Neuroimaging During Pure Oxygen Breathing
Hyperoxia · Hypoxia, Brain · Neurobehavioral Manifestations
Primary: Cerebral Blood Flow — 48.54; 36.17 ml/min/100g tissue — p=<0.05
Phase 3 N=415 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study — -4.1; -5.1 Score on a Scale — p=0.2398
Phase 2 N=330 Study of Debio 1450 for Bacterial Skin Infections
Bacterial Infections
Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…
Phase 2 N=61 A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
Primary Biliary Cholangitis
Primary: Fold Change in Serum Gamma-glutamyl Transferase (GGT) — 0.74; 0.41; 0.28; 0.31 fold-change — p=0.293
N/A N=8 Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms
Breast Cancer
Primary: Assess the Ability of the HD PET/CT to Predict Final Histopathologic NAC Response.
Phase 2 N=34 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Neuroblastoma
Primary: Overall Responses — 3; 18; 12; 1 Participants
Phase 2 N=91 Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
Jaundice, Neonatal · Hyperbilirubinemia, Neonatal
Primary: Total Serum Bilirubin (mg/dL) — 9.82; 9.97; 9.92; 8.48 mg/dL — p==0.0000021
N/A N=100 Effectiveness of Deep Versus Moderate Neuromuscular Blockade
Neuromuscular Blockade
Primary: Minimum Effective Analgesic Dose (MEAD) of Oxycodone at Postoperative Care Unit (PACU) — 8.0; 8.0 mg
N/A N=355 The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 6-11 Months
Enteropathy
Primary: Change in Length-for-age z Score Over 6 Months From Enrollment to End of Study. — -0.14; -0.27; -0.27 z-score
Phase 3 N=355 Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
Anaemia
Primary: Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants — 11.97; 11.86 Grams per deciliter (g/dL) — p=<.0001
Phase 2 N=12 Topical Treatment and Prevalence of P. Acnes
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Phase 2 N=25 Short-term Effects of Leptin in People With Lipodystrophy
Lipodystrophy
Primary: Total Body Insulin Sensitivity — 4.4; 10.9; 5.8; 6.4 mg/kg fat-free mass/min
N/A N=33 Translation of Eye Movement Reading Training to Clinical Practice
Macular Disease
Primary: Change in Reading Performance and Accuracy Using MNREAD. — 22.59; 24.68 Words Per Minuted (WPM) — p=0.876